

Company Commissioned Article

Expanding Access to Medicines in Australia and New Zealand

As the BLOOD 2021 annual scientific meeting gets underway, we at Jazz Pharmaceuticals are thrilled to continue our support, excitingly for the first time as a local Australia/New Zealand affiliate after establishing our presence in these regions earlier this year.

Haematology is the foundation of Jazz's oncology portfolio. While the oncology community is large, as part of our commitment to patient populations with high unmet needs, we have honed in on smaller groups of adults and paediatric patients facing particular challenges. These patients face difficult odds, with limited treatment options and limited survival.

We believe all people, particularly those who live with complex conditions, deserve new therapeutic options. From innovative delivery systems to exploring the potential of precision medicine, we are committed to improving the lives of patients of all ages.

Critical to achieving this goal is access to treatments. As well as collaborating with partners, we are dedicated to broadening our global footprint and reaching as many people as we can. Building on five years of positive experience in Australia, our latest expansion into this territory allows us to extend patient access and care.

At Jazz, we exist to innovate to improve the lives of patients and their families and we are incredibly proud to support BLOOD in this shared aspiration.

Adam Maguire - General Manager, Jazz ANZ (adam.maguire@jazzpharma.com)

Mark Tennyson - Medical Director, Jazz ANZ (mark.tennyson@jazzpharma.com)

Daniel Girdham – Sales & Marketing Manager, Jazz ANZ (daniel.girdham@jazzpharma.com)

Rene Francia – Medical Science Liaison, Jazz ANZ (rene.francia@jazzpharma.com)

Jazz Pharmaceuticals ANZ PTY Limited

One International Towers Sydney

Watermans Quay

Barangaroo NSW 2000

Australia

20th September 2021